Beryl Drugs Ltd: Share Price Analysis, Intrinsic Value & Fundamentals (2025)

Share Price and Basic Stock Data

Last Updated: February 26, 2025, 3:25 am

Market Cap	13.5 Cr.
Current Price	26.6
High / Low	46.0/24.2
Stock P/E	169
Book Value	18.3
Dividend Yield	0.00 %
ROCE	11.6 %
ROE	8.95 %
Face Value	10.0
PEG Ratio	8.36

Stock P/E, Current Price, and Intrinsic Value Over Time

Stock P/E Current Price Intrinsic Value

View Share Price Target for Beryl Drugs Ltd

Competitors of Beryl Drugs Ltd

Stock Name ⇩	Market Cap ⇩	Current Price ⇩	High / Low ⇩	Stock P/E ⇩	Book Value ⇩	Dividend Yield ⇩	ROCE ⇩	ROE ⇩	Face Value ⇩
MPS Pharmaa Ltd	7.42 Cr.	3.88	4.33/3.05		0.80	0.00 %	9.15 %	34.9 %	10.0
Gujarat Themis Biosyn Ltd	2,663 Cr.	244	390/192	50.6	20.5	0.27 %	45.0 %	33.8 %	1.00
Gujarat Terce Laboratories Ltd	57.0 Cr.	76.8	94.9/30.9	19.3	11.9	0.00 %	9.72 %	3.44 %	10.0
Gujarat Inject (Kerala) Ltd	39.4 Cr.	26.9	29.0/8.74	40.2	6.64	0.00 %	2.65 %	2.08 %	10.0
Godavari Drugs Ltd	65.8 Cr.	87.4	155/81.2	10.6	55.4	0.00 %	14.4 %	15.5 %	10.0
Industry Average	13,248.43	N/A		34.39	N/A	N/A	16.05	15.89	N/A

All Competitor Stocks of Beryl Drugs Ltd

Quarterly Result

Metric	Sep 2021	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024
Sales	3.38	3.22	3.52	4.97	7.90	8.19	6.09	8.18	8.09	7.66	3.21	6.29	5.64
Expenses	3.47	2.97	3.81	4.37	7.27	7.47	5.82	7.05	7.37	6.87	3.19	5.30	5.08
Operating Profit	-0.09	0.25	-0.29	0.60	0.63	0.72	0.27	1.13	0.72	0.79	0.02	0.99	0.56
OPM %	-2.66%	7.76%	-8.24%	12.07%	7.97%	8.79%	4.43%	13.81%	8.90%	10.31%	0.62%	15.74%	9.93%
Other Income	-0.00	-0.00	-0.00	-0.00	-0.00	-0.00	-0.00	-0.00	-0.00	-0.00	-0.00	-0.00	-0.00
Interest	0.11	0.12	0.10	0.13	0.11	0.12	0.06	0.12	0.10	0.11	0.13	0.21	0.12
Depreciation	0.24	0.27	0.27	0.25	0.19	0.22	0.15	0.28	0.29	0.31	0.32	0.28	0.33
Profit before tax	-0.44	-0.14	-0.66	0.22	0.33	0.38	0.06	0.73	0.33	0.37	-0.43	0.50	0.11
Tax %	-6.82%	-28.57%	-27.27%	-0.00%	-6.06%	60.53%	-16.67%	27.40%	18.18%	16.22%	-16.28%	26.00%	90.91%
Net Profit	-0.42	-0.10	-0.47	0.22	0.34	0.14	0.06	0.53	0.27	0.31	-0.35	0.37	0.01
EPS in Rs	-0.83	-0.20	-0.93	0.43	0.67	0.28	0.12	1.05	0.53	0.61	-0.69	0.73	0.02

Last Updated: January 5, 2025, 8:34 am

Below is a detailed analysis of the quarterly data for Beryl Drugs Ltd based on the most recent figures (Sep 2024) and their trends compared to the previous period:

For Sales, as of Sep 2024, the value is ₹5.64 Cr.. The value appears to be declining and may need further review. It has decreased from ₹6.29 Cr. (Jun 2024) to ₹5.64 Cr., marking a decrease of ₹0.65 Cr..
For Expenses, as of Sep 2024, the value is ₹5.08 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from ₹5.30 Cr. (Jun 2024) to ₹5.08 Cr., marking a decrease of ₹0.22 Cr..
For Operating Profit, as of Sep 2024, the value is ₹0.56 Cr.. The value appears to be declining and may need further review. It has decreased from ₹0.99 Cr. (Jun 2024) to ₹0.56 Cr., marking a decrease of ₹0.43 Cr..
For OPM %, as of Sep 2024, the value is 9.93%. The value appears to be declining and may need further review. It has decreased from 15.74% (Jun 2024) to 9.93%, marking a decrease of 5.81%.
For Other Income, as of Sep 2024, the value is ₹0.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2024) which recorded ₹0.00 Cr..
For Interest, as of Sep 2024, the value is ₹0.12 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from ₹0.21 Cr. (Jun 2024) to ₹0.12 Cr., marking a decrease of ₹0.09 Cr..
For Depreciation, as of Sep 2024, the value is ₹0.33 Cr.. The value appears to be increasing, which may not be favorable. It has increased from ₹0.28 Cr. (Jun 2024) to ₹0.33 Cr., marking an increase of ₹0.05 Cr..
For Profit before tax, as of Sep 2024, the value is ₹0.11 Cr.. The value appears to be declining and may need further review. It has decreased from ₹0.50 Cr. (Jun 2024) to ₹0.11 Cr., marking a decrease of ₹0.39 Cr..
For Tax %, as of Sep 2024, the value is 90.91%. The value appears to be increasing, which may not be favorable. It has increased from 26.00% (Jun 2024) to 90.91%, marking an increase of 64.91%.
For Net Profit, as of Sep 2024, the value is ₹0.01 Cr.. The value appears to be declining and may need further review. It has decreased from ₹0.37 Cr. (Jun 2024) to ₹0.01 Cr., marking a decrease of ₹0.36 Cr..
For EPS in Rs, as of Sep 2024, the value is ₹0.02. The value appears to be declining and may need further review. It has decreased from ₹0.73 (Jun 2024) to ₹0.02, marking a decrease of ₹0.71.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: September 23, 2024, 2:53 pm

Metric	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	TTM
Sales	14.42	14.54	13.23	12.99	10.90	15.08	12.81	12.78	14.03	14.48	26.82	26.72	25.25
Expenses	13.50	13.77	12.50	12.49	10.96	14.04	11.78	11.87	12.58	14.04	24.82	24.36	22.73
Operating Profit	0.92	0.77	0.73	0.50	-0.06	1.04	1.03	0.91	1.45	0.44	2.00	2.36	2.52
OPM %	6.38%	5.30%	5.52%	3.85%	-0.55%	6.90%	8.04%	7.12%	10.33%	3.04%	7.46%	8.83%	9.98%
Other Income	0.12	0.18	0.18	0.37	0.27	0.69	0.24	0.23	0.64	0.16	0.27	0.40	0.00
Interest	0.14	0.20	0.26	0.21	0.20	0.13	0.15	0.32	0.47	0.46	0.47	0.55	0.55
Depreciation	0.29	0.32	0.52	0.41	0.38	0.33	0.32	0.66	1.27	1.09	0.81	1.20	1.20
Profit before tax	0.61	0.43	0.13	0.25	-0.37	1.27	0.80	0.16	0.35	-0.95	0.99	1.01	0.77
Tax %	36.07%	37.21%	38.46%	32.00%	18.92%	22.05%	26.25%	68.75%	31.43%	-30.53%	22.22%	23.76%
Net Profit	0.39	0.27	0.08	0.17	-0.45	0.99	0.59	0.05	0.24	-0.66	0.77	0.77	0.60
EPS in Rs	0.76	0.53	0.16	0.34	-0.89	1.95	1.16	0.10	0.47	-1.30	1.52	1.52	1.18
Dividend Payout %	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year	2013-2014	2014-2015	2015-2016	2016-2017	2017-2018	2018-2019	2019-2020	2020-2021	2021-2022	2022-2023	2023-2024
YoY Net Profit Growth (%)	-30.77%	-70.37%	112.50%	-364.71%	320.00%	-40.40%	-91.53%	380.00%	-375.00%	216.67%	0.00%
Change in YoY Net Profit Growth (%)	0.00%	-39.60%	182.87%	-477.21%	684.71%	-360.40%	-51.12%	471.53%	-755.00%	591.67%	-216.67%

Beryl Drugs Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2013-2014 to 2023-2024.

Growth

Compounded Sales Growth
10 Years:	6%
5 Years:	16%
3 Years:	24%
TTM:	-32%

Compounded Profit Growth
10 Years:	11%
5 Years:	6%
3 Years:	113%
TTM:	-93%

Stock Price CAGR
10 Years:	-4%
5 Years:	47%
3 Years:	39%
1 Year:	-32%

Return on Equity
10 Years:	3%
5 Years:	2%
3 Years:	4%
Last Year:	9%

Last Updated: Unknown

Balance Sheet

Last Updated: November 14, 2024, 5:42 pm

Month	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Sep 2024
Equity Capital	5.06	5.09	5.09	5.09	5.09	5.09	5.09	5.09	5.09	5.09	5.09	5.09	5.09
Reserves	1.06	1.33	1.40	1.57	0.79	1.57	2.43	2.53	2.84	2.20	2.97	3.83	4.21
Borrowings	0.89	1.53	1.72	1.69	1.72	1.48	3.25	5.23	5.12	5.29	4.54	5.09	4.54
Other Liabilities	1.92	1.79	2.71	1.80	2.85	2.69	3.80	4.07	5.60	5.25	4.92	3.48	3.16
Total Liabilities	8.93	9.74	10.92	10.15	10.45	10.83	14.57	16.92	18.65	17.83	17.52	17.49	17.00
Fixed Assets	2.85	2.79	2.43	2.44	2.25	2.22	1.96	8.60	7.52	6.04	6.03	6.17	7.27
CWIP	0.00	0.13	0.24	0.00	0.00	0.08	6.24	0.00	0.00	0.00	0.00	0.00	0.00
Investments	1.24	0.73	0.68	0.68	0.49	0.22	0.48	0.56	0.12	0.16	0.15	0.00	0.00
Other Assets	4.84	6.09	7.57	7.03	7.71	8.31	5.89	7.76	11.01	11.63	11.34	11.32	9.73
Total Assets	8.93	9.74	10.92	10.15	10.45	10.83	14.57	16.92	18.65	17.83	17.52	17.49	17.00

Below is a detailed analysis of the balance sheet data for Beryl Drugs Ltd based on the most recent figures (Sep 2024) and their trends compared to the previous period:

For Equity Capital, as of Sep 2024, the value is ₹5.09 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded ₹5.09 Cr..
For Reserves, as of Sep 2024, the value is ₹4.21 Cr.. The value appears strong and on an upward trend. It has increased from ₹3.83 Cr. (Mar 2024) to ₹4.21 Cr., marking an increase of ₹0.38 Cr..
For Borrowings, as of Sep 2024, the value is ₹4.54 Cr.. The value appears to be improving (decreasing). However, Borrowings exceed Reserves, which may signal higher financial risk. It has decreased from ₹5.09 Cr. (Mar 2024) to ₹4.54 Cr., marking a decrease of ₹0.55 Cr..
For Other Liabilities, as of Sep 2024, the value is ₹3.16 Cr.. The value appears to be improving (decreasing). It has decreased from ₹3.48 Cr. (Mar 2024) to ₹3.16 Cr., marking a decrease of ₹0.32 Cr..
For Total Liabilities, as of Sep 2024, the value is ₹17.00 Cr.. The value appears to be improving (decreasing). It has decreased from ₹17.49 Cr. (Mar 2024) to ₹17.00 Cr., marking a decrease of ₹0.49 Cr..
For Fixed Assets, as of Sep 2024, the value is ₹7.27 Cr.. The value appears strong and on an upward trend. It has increased from ₹6.17 Cr. (Mar 2024) to ₹7.27 Cr., marking an increase of ₹1.10 Cr..
For CWIP, as of Sep 2024, the value is ₹0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded ₹0.00 Cr..
For Investments, as of Sep 2024, the value is ₹0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded ₹0.00 Cr..
For Other Assets, as of Sep 2024, the value is ₹9.73 Cr.. The value appears to be declining and may need further review. It has decreased from ₹11.32 Cr. (Mar 2024) to ₹9.73 Cr., marking a decrease of ₹1.59 Cr..
For Total Assets, as of Sep 2024, the value is ₹17.00 Cr.. The value appears to be declining and may need further review. It has decreased from ₹17.49 Cr. (Mar 2024) to ₹17.00 Cr., marking a decrease of ₹0.49 Cr..

However, the Borrowings (₹4.54 Cr.) are higher than the Reserves (₹4.21 Cr.), which may signal higher financial risk.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Reserves and Borrowings Chart

Cash Flow

Month	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Cash from Operating Activity +	0.78	0.00	0.70	-0.13	0.37	-0.10	3.35	0.18	0.34	-0.47	2.48	0.82
Cash from Investing Activity +	-0.70	0.00	0.02	0.17	0.32	-0.03	-5.01	-1.55	0.26	0.52	-1.30	-1.08
Cash from Financing Activity +	0.08	0.00	-0.09	-0.23	-0.19	-0.36	1.62	1.67	-0.54	-0.24	-1.17	0.10
Net Cash Flow	0.16	0.00	0.63	-0.19	0.50	-0.49	-0.04	0.30	0.06	-0.18	0.01	-0.16

Free Cash Flow

Month	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Free Cash Flow	0.03	-0.76	-0.99	-1.19	-1.78	-0.44	-2.22	-4.32	-3.67	-4.85	-2.54	-2.73

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

Month	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Debtor Days	56.70	64.26	102.08	100.59	102.47	116.91	98.02	98.53	118.11	112.17	93.83	101.98
Inventory Days	30.75	52.84	64.34	65.28	151.29	53.10	39.74	486.67	1,135.00		245.67	35.00
Days Payable	52.72	50.59	69.91	34.34	65.24	57.03	93.60	755.17	1,110.00		758.08	56.11
Cash Conversion Cycle	34.73	66.51	96.50	131.54	188.52	112.97	44.16	-169.97	143.11	112.17	-418.57	80.87
Working Capital Days	35.69	75.56	84.70	105.37	120.89	105.53	43.59	82.25	120.45	138.39	71.26	93.23
ROCE %	11.59%	8.42%	5.20%	5.56%	-2.26%	11.94%	9.94%	4.06%	2.86%	-3.82%	11.60%	11.05%

Financial Efficiency Indicators Chart

Share Holding Pattern

Month	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024
Promoters	24.92%	24.92%	24.92%	24.92%	24.92%	26.38%	26.38%	26.38%	26.38%	26.38%	26.38%	26.38%
Public	75.08%	75.08%	75.08%	75.07%	75.07%	73.61%	73.61%	73.62%	73.62%	73.61%	73.61%	73.62%
No. of Shareholders	6,974	6,992	6,978	6,978	6,939	6,894	6,800	6,805	6,852	7,257	7,325	7,364

Shareholding Pattern Chart

No. of Shareholders

This stock is not held by any mutual fund

ROCE Trend

EPS Trend

Key Financial Ratios

Month	Mar 18	Mar 17
FaceValue	10.00	10.00
Basic EPS (Rs.)	1.96	0.00
Diluted EPS (Rs.)	1.96	0.00
PBDIT Margin (%)	10.56	1.89
PBIT Margin (%)	8.50	-1.38
PBT Margin (%)	7.67	-3.12
Net Profit Margin (%)	6.21	-3.59
NP After MI And SOA Margin (%)	6.21	-3.59
Interest Coverage Ratio (X)	10.28	-0.79
Interest Coverage Ratio (Post Tax) (X)	8.50	-1.06

After reviewing the key financial ratios for Beryl Drugs Ltd, here is a detailed analysis based on the latest available data and recent trends:

For FaceValue, as of Mar 18, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 17) which recorded 10.00.
For Basic EPS (Rs.), as of Mar 18, the value is 1.96. This value is below the healthy minimum of 5. It has increased from 0.00 (Mar 17) to 1.96, marking an increase of 1.96.
For Diluted EPS (Rs.), as of Mar 18, the value is 1.96. This value is below the healthy minimum of 5. It has increased from 0.00 (Mar 17) to 1.96, marking an increase of 1.96.
For PBDIT Margin (%), as of Mar 18, the value is 10.56. This value is within the healthy range. It has increased from 1.89 (Mar 17) to 10.56, marking an increase of 8.67.
For PBIT Margin (%), as of Mar 18, the value is 8.50. This value is below the healthy minimum of 10. It has increased from -1.38 (Mar 17) to 8.50, marking an increase of 9.88.
For PBT Margin (%), as of Mar 18, the value is 7.67. This value is below the healthy minimum of 10. It has increased from -3.12 (Mar 17) to 7.67, marking an increase of 10.79.
For Net Profit Margin (%), as of Mar 18, the value is 6.21. This value is within the healthy range. It has increased from -3.59 (Mar 17) to 6.21, marking an increase of 9.80.
For NP After MI And SOA Margin (%), as of Mar 18, the value is 6.21. This value is below the healthy minimum of 8. It has increased from -3.59 (Mar 17) to 6.21, marking an increase of 9.80.
For Interest Coverage Ratio (X), as of Mar 18, the value is 10.28. This value is within the healthy range. It has increased from -0.79 (Mar 17) to 10.28, marking an increase of 11.07.
For Interest Coverage Ratio (Post Tax) (X), as of Mar 18, the value is 8.50. This value is within the healthy range. It has increased from -1.06 (Mar 17) to 8.50, marking an increase of 9.56.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of Beryl Drugs Ltd as of February 27, 2025 is: ₹225.87

Calculation basis:

Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of February 27, 2025, Beryl Drugs Ltd is Undervalued by 749.14% compared to the current share price 26.60

Intrinsic Value of Beryl Drugs Ltd as of February 27, 2025 is: 271.53

Calculation basis:

Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of February 27, 2025, Beryl Drugs Ltd is Undervalued by 920.79% compared to the current share price ₹26.60

Last 5 Year EPS CAGR: 20.21%

*Investments are subject to market risks

Strength and Weakness

Unable to fetch valid data for stock valuation.

Stock Analysis

Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Beryl Drugs Ltd:
1. Net Profit Margin: 6.21%
  - Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
2. ROCE: 0% (Industry Average ROCE: 16.05%)
  - ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
3. ROE%: 0% (Industry Average ROE: 15.89%)
  - ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
4. Interest Coverage Ratio (Post Tax): 8.5
  - Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
5. Quick Ratio: 0
  - Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
6. Stock P/E: 169 (Industry average Stock P/E: 34.39)
  - Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
7. Total Debt / Equity: 0
  - Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
Stock Rating:

About the Company - Qualitative Analysis

Beryl Drugs Ltd. is a Public Limited Listed company incorporated on 24/08/1993 and has its registered office in the State of Madhya Pradesh, India. Company's Corporate Identification Number(CIN) is L02423MP1993PLC007840 and registration number is 007840. Currently Company is involved in the business activities of Manufacture of allopathic pharmaceutical preparations. Company's Total Operating Revenue is Rs. 26.73 Cr. and Equity Capital is Rs. 5.09 Cr. for the Year ended 31/03/2024.

INDUSTRY	ADDRESS	CONTACT
Pharmaceuticals	133, Kanchan Bagh, Indore Madhya Pradesh 452001	beryldrugs25@yahoo.com http://www.beryldrugs.com

Management
Name	Position Held
Mr. Sudhir Sethi	Chairman & Director
Mr. Sanjay Sethi	Managing Director
Mr. Abhinav Naik	Independent Director
Mrs. Shreya Saraf	Independent Woman Director

FAQ

What is the latest intrinsic value of Beryl Drugs Ltd?

Let's break down Beryl Drugs Ltd's intrinsic value simply:

We calculate intrinsic value using the PE Ratio Method - comparing the company's current price-to-earnings ratio with its historical average and industry peers. Think of it like checking if a stock is "on sale" compared to its typical pricing.

As of 27 February 2025:

Calculated Fair Value: ₹225.87
Current Market Price: ₹26.60
Variance: 749.14% higher

This suggests Beryl Drugs Ltd is currently undervalued by 749.14%. For context:

Market Cap: 13.5 Cr.
52-Week Range: 46.0/24.2
Reserves (Sep 2024): 4.21 Cr
Liabilities: 17.00 Cr

Remember: The PE method gives a snapshot based on earnings multiples. While useful for quick comparisons, investors should also consider growth prospects, industry trends, and economic conditions. This calculation assumes historical PE ratios remain relevant - always verify with current market dynamics.

What is the Market Cap of Beryl Drugs Ltd?

The Market Cap of Beryl Drugs Ltd is 13.5 Cr..

What is the current Stock Price of Beryl Drugs Ltd as on 27 February 2025?

The current stock price of Beryl Drugs Ltd as on 27 February 2025 is ₹26.6.

What is the High / Low of Beryl Drugs Ltd stocks in FY 2024-2025?

In FY 2024-2025, the High / Low of Beryl Drugs Ltd stocks is 46.0/24.2.

What is the Stock P/E of Beryl Drugs Ltd?

The Stock P/E of Beryl Drugs Ltd is 169.

What is the Book Value of Beryl Drugs Ltd?

The Book Value of Beryl Drugs Ltd is 18.3.

What is the Dividend Yield of Beryl Drugs Ltd?

The Dividend Yield of Beryl Drugs Ltd is 0.00 %.

What is the ROCE of Beryl Drugs Ltd?

The ROCE of Beryl Drugs Ltd is 11.6 %.

What is the ROE of Beryl Drugs Ltd?

The ROE of Beryl Drugs Ltd is 8.95 %.

What is the Face Value of Beryl Drugs Ltd?

The Face Value of Beryl Drugs Ltd is 10.0.